Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis. A Prospective Multicentric Study
Status: Recruiting
Location: See all (15) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Adult patients with a diagnosis of idiopathic retroperitoneal fibrosis Prospective multicentric cohort study Intervention : administration of prednisone during 9 to 21 months at 1mg/kg/day at inclusion.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient over 18 years old
• New onset or untreated relapsing of active idiopathic retroperitoneal fibrosis (IRF) defined by the association of:
• Related-disease symptoms (Appendix 17.2) or elevated CRP level (\>20 mg/l) AND
• Retroperitoneal peri-aortic mass that surrounds the abdominal vessels on CT-scan
Locations
Other Locations
France
Médecine Interne
RECRUITING
Agen
Médecine interne et maladies infectieuses - GH Sud Haut Lévêque
RECRUITING
Bordeaux
Médecine interne - Ambroise Paré
RECRUITING
Boulogne-billancourt
Médecine interne
RECRUITING
Brest
Médecine interne - Henri-Mondor
RECRUITING
Créteil
Médecine interne et immunologie clinique - Dijon
RECRUITING
Dijon
Médecine interne - Lille
ACTIVE_NOT_RECRUITING
Lille
Médecine Interne - La Timone
RECRUITING
Marseille
Médecine Interne - Bichat
RECRUITING
Paris
Médecine interne - Cochin
RECRUITING
Paris
Médecine interne - Saint Antoine
RECRUITING
Paris
Médecine Interne, Vascularites et Myosites - La Pitié Salpêtrière
RECRUITING
Paris
Médecine vasculaire - HEGP
RECRUITING
Paris
Néphrologie - Bichat
ACTIVE_NOT_RECRUITING
Paris
Médecine interne - Delafontaine
ACTIVE_NOT_RECRUITING
Saint-denis
Contact Information
Primary
Karim SACRE
karim.sacre@aphp.fr
01.40.25.60.19
Backup
Khadija BENALI
khadija.benali@aphp.fr
01.40.25.64.15
Time Frame
Start Date: 2022-11-25
Estimated Completion Date: 2028-11-25
Participants
Target number of participants: 41
Treatments
Experimental: Prednisone
Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris